The Queen Elizabeth Hospital Birmingham has been at the forefront of treatment and research in amyloidosis for over 20 years. The Midlands Amyloidosis Service (MAS) officially launched in August 2019 in response to an increasing awareness of this disease, the availability of new treatments and the recognition that outcomes of heart transplantation in amyloidosis are similar to patients undergoing transplantation for other causes. The service consists of a large multidisciplinary team led by consultants in Cardiology, Haematology, Renal, Neurology and Genetics. The team has forged close links with the National Amyloidosis Centre (Royal Free Hospital, London) and we have recently been awarded NHS Highly Specialised Commissioning to enable us to form part of a wider UK amyloidosis network. MAS clinicians are involved in discussing patients at regular video multidisciplinary meetings, which helps facilitate access to cutting-edge treatments and in many cases avoids unnecessary travel for patients.